In patients with NSCLC CNS disease, mutations in EGFR (36% vs 17%, P < .001) and KRAS (18% vs 14%, P = .19) were more frequent than in the non-CNS cohort (Figure 3B). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.